Healthcare / BiotechnologyNasdaqGM
$11.37
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-35.1M · quality 50.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
1/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$651M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-37.3%
↓Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.91x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-59.9M · FCF $-54.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Net Income | $-59.9M | $-59.9M | $-73.9M | $-35.1M | $-45.2M | $-47.5M | $-20.7M |
| EBITDA | $-67.8M | $-67.8M | $-82.0M | — | — | — | — |
| EPS | -0.88 | -0.88 | -1.53 | -1.30 | -1.72 | -4.24 | — |
| Cash Flow | |||||||
| Free Cash Flow | $-54.5M | $-54.5M | $-15.6M | — | — | — | — |
| Returns | |||||||
| ROE | -37.3% | -37.3% | -34.9% | -32.6% | -35.2% | -28.4% | 82.7% |
| Growth & Yield | |||||||
| EPS Growth | 42.5% | 42.5% | -17.7% | 24.4% | 59.4% | — | — |
Returns (%)
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.